304 results on '"Avigan, Mark"'
Search Results
2. Consensus Guidelines: Best Practices for the Prevention, Detection and Management of Hepatitis B Virus Reactivation in Clinical Trials with Immunosuppressive/Immunomodulatory Therapy
3. Drug-Induced Liver Injury in the Elderly: Consensus Statements and Recommendations from the IQ-DILI Initiative
4. A preclinical model of severe NASH-like liver injury by chronic administration of a high-fat and high-sucrose diet in mice
5. Correction to: Drug-Induced Liver Injury in the Elderly: Consensus Statements and Recommendations from the IQ-DILI Initiative
6. Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report
7. Lipidomic profiling of the hepatic esterified fatty acid composition in diet-induced nonalcoholic fatty liver disease in genetically diverse Collaborative Cross mice
8. Repeated or Continuous Medically Supervised Ketamine Administration Associated with Hepatobiliary Adverse Events: A Retrospective Case Series
9. Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development
10. Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis
11. An Evaluation of Postmarketing Reports of Serious Idiosyncratic Liver Injury Associated with Ulipristal Acetate for the Treatment of Uterine Fibroids
12. Deciphering the Dynamic Complexities of the Liver Microenvironment — Toward a Better Understanding of Immune-Mediated liver Injury Caused by Immune Checkpoint Inhibitors (ILICI)
13. Liver biopsy for assessment of suspected drug‐induced liver injury in metabolic dysfunction‐associated steatohepatitis clinical trials: Expert consensus from the Liver Forum
14. Liver biopsy for assessment of suspected drug‐induced liver injury in metabolic dysfunction‐associated steatohepatitis clinical trials: Expert consensus from the Liver Forum.
15. Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report
16. Perspectives on the Regulatory and Clinical Science of Drug-Induced Liver Injury (DILI)
17. Effect of an obesogenic high-fat and high-sucrose diet on hepatic gene expression signatures in male Collaborative Cross mice
18. Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity
19. Non-alcoholic fatty liver disease-associated DNA methylation and gene expression alterations in the livers of Collaborative Cross mice fed an obesogenic high-fat and high-sucrose diet
20. Acute Cholecystitis Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists Reported to the US Food and Drug Administration
21. Research Directions in Genetic Predispositions to Stevens–Johnson Syndrome / Toxic Epidermal Necrolysis
22. Data Mining of the US FDA’s Adverse Events Reporting System Database to Evaluate Drug–Drug Interactions Associated with Statin-Induced Rhabdomyolysis
23. Co‐Culture of Human Primary Hepatocytes and Nonparenchymal Liver Cells in the Emulate® Liver‐Chip for the Study of Drug‐Induced Liver Injury
24. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients
25. John R. Senior, MD
26. Liver Safety Assessment: Required Data Elements and Best Practices for Data Collection and Standardization in Clinical Trials
27. The Clinical Liver Safety Assessment Best Practices Workshop: Rationale, Goals, Accomplishments and the Future
28. Consensus guidelines: best practices for detection, assessment and management of suspected acute drug‐induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease
29. Profiling Cumulative Proportional Reporting Ratios of Drug-Induced Liver Injury in the FDA Adverse Event Reporting System (FAERS) Database
30. DILI and Drug Development: A Regulatory Perspective
31. Informatic Tools and Approaches in Postmarketing Pharmacovigilance Used by FDA
32. An Observational Study of Cholecystectomy in Patients Receiving Tegaserod
33. Regulatory Perspectives
34. List of Contributors
35. Validity of diagnostic codes to identify cases of severe acute liver injury in the U.S. Food and Drug Administrationʼs Mini-Sentinel Distributed Database
36. Spontaneous Reports of Seizure in Association With Leuprolide (Lupron Depot), Goserelin (Zoladex Implant), and Naferelin (Synarel Nasal Spray)
37. A case series analysis of serious exacerbations of viral hepatitis and non‐viral hepatic injuries in tocilizumab‐treated patients
38. Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis
39. Characterization of the variability in the extent of nonalcoholic fatty liver induced by a high‐fat diet in the genetically diverse Collaborative Cross mouse model
40. Sodium Phosphate Tablets and Acute Phosphate Nephropathy
41. Finding, evaluating, and managing drug-related risks: approaches taken by the US Food and Drug Administration (FDA)
42. Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors†
43. Pharmacogenomic biomarkers of susceptibility to adverse drug reactions: just around the corner or pie in the sky?
44. An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDAʼs spontaneous adverse event reporting system†
45. Using controlled clinical trials to learn more about acute drug-induced liver injury
46. Rhabdomyolysis reports show interaction between simvastatin and CVP3A4 inhibitors: 71
47. Rhabdomyolysis Reports Show Interaction between Simvastatin and CYP3A4 Inhibitors: 526.
48. Black cohosh: considerations of safety and benefit
49. Brief Communication: Characteristics of Spontaneous Cases of Tuberculosis Associated with Infliximab
50. Recent Trends in Acetaminophen-Associated Overdoses in the United States, 2003 to 2005: 372.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.